Adverse effects of advanced glycation end products on embryonal development

Acta Med Okayama. 2008 Apr;62(2):93-9. doi: 10.18926/AMO/30960.

Abstract

We studied the effects of advanced glycation end products (AGEs), which are known to accumulate in patients with diabetes, autoimmune diseases, or those who smoke, on embryonal development. Pronuclear (PN) embryos were obtained by flushing the fallopian tubes of rats after superovulation and mating. The cleavage rate and blastocyst yield were evaluated at 24, 72, 96, and 120 h of culture. Glyoxal, an AGE-forming aldehyde, suppressed embryonal development at every stage from PN to blastocyst in a concentration-dependent manner. The cleavage rate of the embryo was also signifi cantly decreased by treatment with glyoxal at concentrations of 1 mM or higher. The blastocyst yield was significantly decreased by treatment with glyoxal at concentrations of 0.5 mM or higher. N-acetyl-L-cysteine (L-NAC) at 1 mM significantly suppressed the glyoxal-induced embryonal toxicity. BSA-AGEs at 5 microg/ml or higher concentration signifi cantly reduced the cleavage rate and blastocyst yield compared to those for BSA-treated embryos. L-NAC at 1 mM significantly suppressed BSAAGE-induced embryonal toxicity. Because AGEs are embryo-toxic, AGE contamination may influence the pregnancy rate of in vitro fertilization and embryo transfer. AGEs, which are increased in women under pathological conditions, may also be involved in their infertility.

MeSH terms

  • Animals
  • Embryo, Mammalian / cytology
  • Embryo, Mammalian / drug effects*
  • Embryo, Mammalian / physiology
  • Female
  • Gestational Age
  • Glycation End Products, Advanced / metabolism
  • Glycation End Products, Advanced / pharmacology*
  • Glyoxal / metabolism
  • Glyoxal / pharmacology*
  • Humans
  • Male
  • Pregnancy
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Glycation End Products, Advanced
  • Glyoxal